Biora Therapeutics, Inc.
BIOR · OTC
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.00 | 0.08 | 0.24 | -2.01 |
| FCF Yield | -228.24% | -25.94% | -8.38% | -5.76% |
| EV / EBITDA | -0.47 | -9.37 | -12.44 | -28.54 |
| Quality | ||||
| ROIC | 232.28% | -194.10% | -249.20% | -96.58% |
| Gross Margin | 100.00% | 100.00% | 100.00% | -25.73% |
| Cash Conversion Ratio | 0.39 | 1.69 | 0.94 | 0.86 |
| Growth | ||||
| Revenue 3-Year CAGR | -85.25% | -83.99% | -79.46% | -16.57% |
| Free Cash Flow Growth | 25.47% | 61.26% | 1.38% | -55.38% |
| Safety | ||||
| Net Debt / EBITDA | -0.28 | -2.65 | -0.23 | -0.64 |
| Interest Coverage | -6.84 | -5.62 | -9.33 | -10.85 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.35 | 0.67 | 7.65 |
| Cash Conversion Cycle | 73,867.78 | 587.25 | -1,475.62 | 12.43 |